DOYLESTOWN, Pa., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical…
– Post-hoc analysis from pivotal Phase 3 REST-ON trial confirmed the efficacy of LUMRYZ in study participants who were and…
BEDFORD, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed…
Data Readout Expected Early Calendar 2025; NDA Submission on Track for 1H Calendar 2025PRINCETON, N.J., Sept. 25, 2024 (GLOBE NEWSWIRE)…
$185+ million in incremental orders for ACAM2000® and VIGIV to be delivered in 2024 and 2025GAITHERSBURG, Md., Sept. 25, 2024…
Genespire raises €46.6 million (~$52 million) in a Series B round to advance its first pediatric in-vivo gene therapy into…
LUND, SE / ACCESSWIRE / September 25, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today presented data from…
PRINCETON, N.J., Sept. 24, 2024 /PRNewswire/ -- WCG, the global leader in providing solutions that measurably improve and accelerate clinical research,…
ADELAIDE, South Australia, Sept. 24, 2024 /PRNewswire/ -- BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organization (CDMO),…
USA News Group CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, Sept. 24, 2024 /PRNewswire/ -- USA News Group – Health…